Пульс - медицинский центр 
Пульс - медицинский центр
Круглосуточно
бесплатно по России
+7 (965) 177 17 74
бесплатно по России
Considering that a similar picture took place in previous years, in Ukraine there was an accumulation of a layer susceptible to poliomyelitis among the child population. In addition, since April 2016, the oral (live) polio vaccine (OPV), which is used in Ukraine, since the 3rd vaccination, does not contain type 2 poliovirus (two-component OPV, which is now used worldwide, contains only polioviruses). ). type ov1 and 3). This also contributes to a decrease in both individual and population immunity to type 2 poliovirus. The result was an outbreak of poliomyelitis caused by vaccine-derived type 2 poliovirus (a vaccine-derived virus that acquired neurovirulent properties during circulation in a low immune population.). There was no adequate response to this outbreak, namely additional vaccination rounds for children under 6 years of age to stop the circulation of the vaccine-related virus. In January 2022, a new outbreak emerged.
According to him, now there are 5.5 thousand patients in hospitals who have been diagnosed with coronavirus disease. Of these, 2,300 are on beds with oxygen therapy, and most of them receive it. To prevent logistical problems, at the end of last year, state funding was allocated through several mechanisms: one in the form of centralized purchases, one in the form of subventions provided to the regions in order to purchase autonomous sources of oxygen supply. On September 15, the Ministry of Health sent 124,608 packages of the Paxclovid drug for coronavirus disease to the regions. The medicine is prescribed primarily to patients at risk to prevent the complex course of coronavirus disease.
It is the transition to the use of IPV in Ukraine for all doses of the Immunization Schedule that should be the next task for vaccination. For this, several mechanisms can be used, including humanitarian assistance, the conclusion of planned direct contracts with vaccine manufacturers based on the needs of the required composition of vaccines according to the Calendar, in particular, taking into account the existence of modern combined vaccines with IPV, which can also be used at an older age. In the absence of combination vaccines with IPV, IPV can be used as a single vaccine.
5-ASA preparations have very weak immunosuppressive activity. There are no reports that these drugs are associated with an increased risk of infection, and studies evaluating the safety profile of 5-ASA do not show an increased risk of serious or opportunistic infections. Treatment with 5-ASA should be continued without concern for an increased risk of infection or severe COVID-19. If the patient is in contact with a patient with COVID-19 or develops COVID-19, treatment with 5-ASA should be continued.
Закажите обратный звонок
Задать вопрос
Быстрая запись на прием